J. M. Seeger, Management of patients with prosthetic vascular graft infection, Am Surg, vol.66, pp.166-77, 2000.

R. Chiesa, D. Astore, S. Frigerio, L. Garriboli, G. Piccolo et al., Vascular prosthetic graft infection: epidemiology, bacteriology, pathogenesis and treatment

, Acta Chir Belg, vol.102, pp.238-285, 2002.

P. D. Hayes, A. Nasim, N. J. London, R. D. Sayers, W. W. Barrie et al., situ replacement of infected aortic grafts with rifampicin-bonded prostheses: the Leicester experience, vol.30, pp.92-100, 1992.

G. S. Oderich, T. C. Bower, K. J. Cherry, J. M. Panneton, T. M. Sullivan et al., Evolution from axillofemoral to in situ prosthetic reconstruction for the treatment of aortic graft infections at a single center, J Vasc Surg, vol.43, pp.1166-74, 2006.

S. F. Fitzgerald, C. Kelly, and H. Humphreys, Diagnosis and treatment of prosthetic aortic graft infections: confusion and inconsistency in the absence of evidence or consensus

, J Antimicrob Chemother, vol.56, pp.996-1005, 2005.

P. J. O'hara, N. R. Hertzer, E. G. Beven, and L. P. Krajewski, Surgical management of infected abdominal aortic grafts: review of a 25-year experience, J Vasc Surg, vol.3, pp.725-756, 1986.

R. J. Valentine, Diagnosis and management of aortic graft infection, Semin Vasc Surg, vol.14, pp.292-301, 2001.

W. J. Sharp, J. J. Hoballah, C. R. Mohan, T. F. Kresowik, M. Martinasevic et al., The management of the infected aortic prosthesis: a current decade of experience, J Vasc Surg, vol.19, pp.844-50, 1994.

E. Kieffer, D. Gomes, L. Chiche, M. Fléron, F. Koskas et al., Allograft replacement for infrarenal aortic graft infection: early and late results in 179 patients, J Vasc Surg, vol.39, pp.1009-1026, 2004.

M. Batt, E. Jean-baptiste, O. Connor, S. Feugier, P. Haulon et al., Contemporary management of infrarenal aortic graft infection: early and late results in 82 patients, Vascular, vol.20, pp.129-166, 2012.

M. Batt, J. Magne, P. Alric, A. Muzj, C. Ruotolo et al., In situ revascularization with silver-coated polyester grafts to treat aortic infection: early and midterm results, J Vasc Surg, vol.38, pp.983-992, 2003.

M. D. Taylor and L. M. Napolitano, Methicillin-resistant Staphylococcus aureus infections in vascular surgery: increasing prevalence, Surg Infect, vol.5, pp.180-187, 2004.

M. Garot, P. Delannoy, A. Meybeck, B. Sarraz-bournet, P. Elia et al., Intra-abdominal aortic graft infection: prognostic factors associated with in-hospital mortality, BMC Infect Dis, vol.14, 2014.

B. R. Saleem, R. Meerwaldt, I. Tielliu, E. Verhoeven, J. Van-den-dungen et al., Conservative treatment of vascular prosthetic graft infection is associated with high mortality, Am J Surg, vol.200, pp.47-52, 2010.

L. Legout, D. 'elia, P. V. Sarraz-bournet, B. Haulon, S. Meybeck et al., Diagnosis and management of prosthetic vascular graft infections, Médecine Mal Infect, vol.42, pp.102-111, 2012.

A. T. Ali, J. G. Modrall, J. Hocking, R. J. Valentine, H. Spencer et al., Long-term results of the treatment of aortic graft infection by in situ replacement with femoral popliteal vein grafts, J Vasc Surg, vol.50, pp.30-39, 2009.

D. F. Bandyk, M. L. Novotney, B. L. Johnson, M. R. Back, and S. R. Roth, Use of rifampin-soaked gelatin-sealed polyester grafts for in situ treatment of primary aortic and vascular prosthetic infections, J Surg Res, vol.95, pp.44-53, 2001.

P. D. Hayes, A. Nasim, N. J. London, R. D. Sayers, W. W. Barrie et al., situ replacement of infected aortic grafts with rifampicin-bonded prostheses: the Leicester experience, 1992.

T. M. Ng, W. X. Khong, P. Harris, P. P. De, A. Chow et al., Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae, PloS One, vol.11, p.153696, 2016.

P. D. Tamma, J. H. Han, C. Rock, A. D. Harris, E. Lautenbach et al., Carbapenem Therapy Is Associated With Improved Survival Compared With PiperacillinTazobactam for Patients With Extended-Spectrum -Lactamase Bacteremia, Clin Infect Dis, 2015.

P. Harris, P. A. Tambyah, D. C. Lye, Y. Mo, T. H. Lee et al., Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial, JAMA, vol.320, pp.984-94, 2018.

M. Revest, F. Camou, E. Senneville, J. Caillon, F. Laurent et al., Medical treatment of prosthetic vascular graft infections: Review of the literature and proposals of a Working Group, Int J Antimicrob Agents, vol.46, pp.254-65, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01162387

G. Lesèche, Y. Castier, M. D. Petit, P. Bertrand, M. Kitzis et al., Long-term results of cryopreserved arterial allograft reconstruction in infected prosthetic grafts and mycotic aneurysms of the abdominal aorta, J Vasc Surg, vol.34, pp.616-638, 2001.

H. Arbatli, R. Degeest, E. Demirsoy, F. Wellens, I. Degrieck et al., Management of infected grafts and mycotic aneurysms of the aorta using cryopreserved homografts, Cardiovasc Surg Lond Engl, vol.11, pp.257-63, 2003.

A. R. Naylor, P. D. Hayes, and S. Darke, A prospective audit of complex wound and graft infections in Great Britain and Ireland: the emergence of MRSA, Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg, vol.21, pp.289-94, 2001.

L. Legout, P. Elia, P. Devos, N. Ettahar, B. Sarraz-bournet et al., Risk factors for methicillin-resistant staphylococcal vascular graft infection in an 11-year cohort study, J Infect, vol.64, pp.441-445, 2012.

O. Lesens, E. Brannigan, C. Bergin, D. Christmann, and Y. Hansmann, Impact of the use of aminoglycosides in combination antibiotic therapy on septic shock and mortality due to Staphylococcus aureus bacteremia, Eur J Intern Med, vol.17, pp.276-80, 2006.

M. Paul, I. Benuri-silbiger, K. Soares-weiser, and L. Leibovici, Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials, BMJ, vol.328, p.668, 2004.

D. T. Baril, D. Silverberg, S. H. Ellozy, A. Carroccio, T. S. Jacobs et al., Endovascular stent-graft repair of failed endovascular abdominal aortic aneurysm repair, Ann Vasc Surg, vol.22, pp.30-36, 2008.

G. S. Oderich, T. C. Bower, K. J. Cherry, J. M. Panneton, T. M. Sullivan et al., Evolution from axillofemoral to in situ prosthetic reconstruction for the treatment of aortic graft infections at a single center, J Vasc Surg, vol.43, pp.1166-74, 2006.

M. Batt, E. Jean-baptiste, O. Connor, S. Saint-lebes, B. Feugier et al., Early and Late Results of Contemporary Management of 37 Secondary Aortoenteric Fistulae, Eur J Vasc Endovasc Surg, vol.41, pp.748-57, 2011.

M. Puges, S. Pereyre, X. Bérard, I. Accoceberry, L. Roy et al., Comparison of Genus Specific PCR and Culture with or without Sonication for Microbiological Diagnosis of Vascular Graft Infection, Eur J Vasc Endovasc Surg, 2018.

A. B. Voorhees, A. Jaretzki, and A. H. Blakemore, The use of tubes constructed from vinyon "N" cloth in bridging arterial defects, Ann Surg, vol.135, pp.332-338, 1952.

, Commission Nationale d'évaluation des dispositifs medicaux et des technologies de santé, 2013.

N. Australia, A. Zealand-;-davies, D. Jones, M. Bailey, J. Beca et al., Extracorporeal Membrane Oxygenation (ANZ ECMO) Influenza Investigators

, Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress Syndrome, JAMA, vol.302, pp.1888-95, 2009.

L. M. Baddour, M. A. Bettmann, A. F. Bolger, A. E. Epstein, P. Ferrieri et al., Nonvalvular cardiovascular device-related infections, Circulation, vol.108, pp.2015-2046, 2003.

L. M. Baddour, M. A. Bettmann, A. F. Bolger, A. E. Epstein, P. Ferrieri et al., Nonvalvular cardiovascular device-related infections, Circulation, vol.108, pp.2015-2046, 2003.

R. Chiesa, D. Astore, S. Frigerio, L. Garriboli, G. Piccolo et al., Vascular prosthetic graft infection: epidemiology, bacteriology, pathogenesis and treatment

, Acta Chir Belg, vol.102, pp.238-285, 2002.

L. Legout, B. Sarraz-bournet, D. Elia, P. V. Devos, P. Pasquet et al., Characteristics and prognosis in patients with prosthetic vascular graft infection: a prospective observational cohort study, Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis, vol.18, pp.352-360, 2012.

M. Batt, E. Jean-baptiste, O. Connor, S. Feugier, P. Haulon et al., Contemporary management of infrarenal aortic graft infection: early and late results in 82 patients, Vascular, vol.20, pp.129-166, 2012.

S. F. Fitzgerald, C. Kelly, and H. Humphreys, Diagnosis and treatment of prosthetic aortic graft infections: confusion and inconsistency in the absence of evidence or consensus

, J Antimicrob Chemother, vol.56, pp.996-1005, 2005.

H. L. Anderson, M. B. Shapiro, R. E. Delius, C. N. Steimle, R. A. Chapman et al., Extracorporeal life support for respiratory failure after multiple trauma, J Trauma, vol.37, pp.266-72, 1994.

E. H. Murphy, W. Y. Szeto, B. J. Herdrich, B. M. Jackson, G. J. Wang et al., The management of endograft infections following endovascular thoracic and abdominal aneurysm repair, J Vasc Surg, vol.58, pp.1179-85, 2013.

S. O'connor, P. Andrew, M. Batt, and J. P. Becquemin, A systematic review and meta-analysis of treatments for aortic graft infection, J Vasc Surg, vol.44, pp.38-45, 2006.

G. S. Oderich, T. C. Bower, J. Hofer, M. Kalra, A. A. Duncan et al., In situ rifampin-soaked grafts with omental coverage and antibiotic suppression are durable with low reinfection rates in patients with aortic graft enteric erosion or fistula, J Vasc Surg, vol.53, pp.106-107, 2011.

E. Jean-baptiste, N. Blanchemain, C. Neut, F. Chai, M. Maton et al., Evaluation of the anti-infectious properties of polyester vascular prostheses functionalised with cyclodextrin, J Infect, vol.68, pp.116-140, 2014.

V. S. Antonios, A. A. Noel, J. M. Steckelberg, W. R. Wilson, J. N. Mandrekar et al., Prosthetic vascular graft infection: A risk factor analysis using a case-control study

, J Infect, vol.53, pp.49-55, 2006.

M. Revest, F. Camou, E. Senneville, J. Caillon, F. Laurent et al., Medical treatment of prosthetic vascular graft infections: Review of the literature and proposals of a Working Group, Int J Antimicrob Agents, vol.46, pp.254-65, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01162387

A. Nasim, M. M. Thompson, A. R. Naylor, P. R. Bell, and N. J. London, The impact of MRSA on vascular surgery, Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg, vol.22, pp.211-215, 2001.

A. R. Naylor, P. D. Hayes, and S. Darke, A prospective audit of complex wound and graft infections in Great Britain and Ireland: the emergence of MRSA, Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg, vol.21, pp.289-94, 2001.

S. E. Cowie, I. Ma, S. K. Lee, R. M. Smith, and Y. N. Hsiang, Nosocomial MRSA infection in vascular surgery patients: impact on patient outcome, Vasc Endovascular Surg, vol.39, pp.327-361, 2005.

L. Legout, P. Elia, P. Devos, N. Ettahar, B. Sarraz-bournet et al., Risk factors for methicillin-resistant staphylococcal vascular graft infection in an 11-year cohort study, J Infect, vol.64, pp.441-445, 2012.

J. H. Matsuura, D. Rosenthal, E. D. Wellons, C. S. Castronovo, and D. Fronk, Hemodialysis graft infections treated with cryopreserved femoral vein, Cardiovasc Surg Lond Engl, vol.10, pp.561-566, 2002.

P. J. Dimuzio, L. M. Reilly, and R. J. Stoney, Redo aortic grafting after treatment of aortic graft infection, J Vasc Surg, vol.24, pp.336-337, 1996.

R. C. Darling, M. Resnikoff, P. B. Kreienberg, B. B. Chang, P. S. Paty et al., Alternative approach for management of infected aortic grafts, J Vasc Surg, vol.25, pp.106-118, 1997.

L. Legout, D. 'elia, P. V. Sarraz-bournet, B. Haulon, S. Meybeck et al., Diagnosis and management of prosthetic vascular graft infections, Médecine Mal Infect, vol.42, pp.102-111, 2012.

R. A. Yeager, D. B. Mcconnell, T. M. Sasaki, and R. M. Vetto, Aortic and peripheral prosthetic graft infection: differential management and causes of mortality, Am J Surg, vol.150, pp.36-43, 1985.

M. Batt, E. Jean-baptiste, O. Connor, S. Saint-lebes, B. Feugier et al., Early and Late Results of Contemporary Management of 37 Secondary Aortoenteric Fistulae, Eur J Vasc Endovasc Surg, vol.41, pp.748-57, 2011.

E. Kieffer, D. Gomes, L. Chiche, M. Fléron, F. Koskas et al., Allograft replacement for infrarenal aortic graft infection: early and late results in 179 patients, J Vasc Surg, vol.39, pp.1009-1026, 2004.

G. Lesèche, Y. Castier, M. D. Petit, P. Bertrand, M. Kitzis et al., Long-term results of cryopreserved arterial allograft reconstruction in infected prosthetic grafts and mycotic aneurysms of the abdominal aorta, J Vasc Surg, vol.34, pp.616-638, 2001.

B. R. Saleem, R. Meerwaldt, I. Tielliu, E. Verhoeven, J. Van-den-dungen et al., Conservative treatment of vascular prosthetic graft infection is associated with high mortality, Am J Surg, vol.200, pp.47-52, 2010.

W. C. Rottier, H. Ammerlaan, and M. Bonten, Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum ?-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis, J Antimicrob Chemother, vol.67, pp.1311-1331, 2012.

J. Oteo, M. Pérez-vázquez, and J. Campos, Extended-spectrum [beta]-lactamase producing Escherichia coli: changing epidemiology and clinical impact, Curr Opin Infect Dis, vol.23, pp.320-326, 2010.

, L'evolution des consommations d'antibiotiques en France entre, Janvier 2017 ANSM, 2000.

P. Nordmann, T. Naas, and L. Poirel, Global spread of Carbapenemase-producing Enterobacteriaceae, Emerg Infect Dis, vol.17, pp.1791-1799, 2011.

M. Szczot, A. Meybeck, L. Legout, A. Pasquet, N. Van-grunderbeeck et al., Vascular graft infections in the intensive care unit: Clinical spectrum and prognostic factors, J Infect, vol.62, pp.204-215, 2011.

, Surveillance des infections nosocomiales en réanimation adulte / 2018 / Maladies infectieuses / Rapports et synthèses / Publications et outils / Accueil n.d, 2018.

J. Cremniter, A. Slassi, J. Quincampoix, V. Sivadon-tardy, T. Bauer et al., Decreased susceptibility to teicoplanin and vancomycin in coagulase-negative Staphylococci isolated from orthopedic-device-associated infections, J Clin Microbiol, vol.48, pp.1428-1459, 2010.

C. González, M. Rubio, J. Romero-vivas, M. González, and J. J. Picazo, Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.29, pp.1171-1178, 1999.

A. Soriano, F. Marco, J. A. Martínez, E. Pisos, M. Almela et al., Influence of vancomycin minimum inhibitory concentration on the treatment of methicillinresistant Staphylococcus aureus bacteremia, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.46, pp.193-200, 2008.

T. P. Lodise, J. Graves, A. Evans, E. Graffunder, M. Helmecke et al., Relationship between vancomycin MIC and failure among patients with methicillinresistant Staphylococcus aureus bacteremia treated with vancomycin, Antimicrob Agents Chemother, vol.52, pp.3315-3335, 2008.

L. K. Hidayat, D. I. Hsu, R. Quist, K. A. Shriner, and A. Wong-beringer, High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity, Arch Intern Med, vol.166, pp.2138-2182, 2006.

T. L. Holland, C. Arnold, and V. G. Fowler, Clinical management of Staphylococcus aureus bacteremia: a review, JAMA, vol.312, pp.1330-1371, 2014.

V. G. Fowler, H. W. Boucher, G. R. Corey, E. Abrutyn, A. W. Karchmer et al., Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus, N Engl J Med, vol.355, pp.653-65, 2006.

L. Legout, P. Delia, B. Sarraz-bournet, C. Rouyer, M. Massongo et al., Factors predictive of treatment failure in staphylococcal prosthetic vascular graft infections: a prospective observational cohort study: impact of rifampin, BMC Infect Dis, vol.14, 2014.

, Statistiques de résistance dans des infections documentées et dans des contexte épidémiologiques

. Rea-/, Surveillance en incidence / Surveillance des infections associées aux soins (IAS) / Infections associées aux soins / Maladies infectieuses / Dossiers thématiques, 2018.

C. Brun-buisson, P. Legrand, A. Philippon, F. Montravers, M. Ansquer et al., Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae, Lancet Lond Engl, vol.2, pp.302-308, 1987.

H. S. Sader, A. Hsiung, T. R. Fritsche, and R. N. Jones, Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype, Diagn Microbiol Infect Dis, vol.57, pp.341-345, 2007.

V. J. Labombardi, A. Rojtman, and K. Tran, Use of cefepime for the treatment of infections caused by extended spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli, Diagn Microbiol Infect Dis, vol.56, pp.313-318, 2006.

G. Zanetti, F. Bally, G. Greub, J. Garbino, T. Kinge et al., Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study, Antimicrob Agents Chemother, vol.47, pp.3442-3449, 2003.

N. Lee, C. Lee, W. Huang, K. Tsui, P. Hsueh et al., Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum betalactamase-producing Enterobacteriaceae: MIC matters, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.56, pp.488-95, 2013.

K. Z. Vardakas, G. S. Tansarli, P. I. Rafailidis, and M. E. Falagas, Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum ?-lactamases: a systematic review and meta-analysis, J Antimicrob Chemother, vol.67, pp.2793-803, 2012.

T. M. Ng, W. X. Khong, P. Harris, P. P. De, A. Chow et al., Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae, PloS One, vol.11, p.153696, 2016.

P. D. Tamma, J. H. Han, C. Rock, A. D. Harris, E. Lautenbach et al., Carbapenem Therapy Is Associated With Improved Survival Compared With PiperacillinTazobactam for Patients With Extended-Spectrum -Lactamase Bacteremia, Clin Infect Dis, 2015.

P. Harris, P. A. Tambyah, D. C. Lye, Y. Mo, T. H. Lee et al., Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial, JAMA, vol.320, pp.984-94, 2018.

O. Lesens, E. Brannigan, C. Bergin, D. Christmann, and Y. Hansmann, Impact of the use of aminoglycosides in combination antibiotic therapy on septic shock and mortality due to Staphylococcus aureus bacteremia, Eur J Intern Med, vol.17, pp.276-80, 2006.

P. G. Pappas, C. A. Kauffman, D. R. Andes, C. J. Clancy, K. A. Marr et al., Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.62, pp.1-50, 2016.

R. M. Young, K. J. Cherry, P. M. Davis, P. Gloviczki, T. C. Bower et al., The results of in situ prosthetic replacement for infected aortic grafts, Am J Surg, vol.178, pp.136-176, 1999.

I. Töpel, F. Audebert, T. Betz, and M. G. Steinbauer, Microbial spectrum and primary resistance to rifampicin in infectious complications in vascular surgery: limits to the use of rifampicin-bonded prosthetic grafts, Angiology, vol.61, pp.423-429, 2010.

. Vi and . Serment,

, Au moment d'être admis à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité?deshérité?des circonstances pour forcer les consciences. Je donnerai mes soins à l'indigent et à quiconque me les demandera, J'informerai les patients des décisions envisagées, de leurs raisons et de leurs conséquences

, Reçu à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs. Je ferai tout pour soulager les souffrances. Je ne prolongerai pas abusivement les agonies

, Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés. J'apporterai mon aide à mes confrères ainsi qu

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses

. Paris, , vol.10, 2018.

M. Maxime and P. Re?fre?f,

. Monsieur,

, Vous nous avez sollicite?ssollicite?s a? propos d'un projet intitule?:intitule?: Réévaluation du protocole antiinfectieux probabiliste au cours de la prise en charge des infections de prothèses vasculaires aortiques

. Cette-e?tudee?tude, ne soule? ve pas de proble? me e?thiquee?thique particulier et ne rele? ve pas du domaine d'application de la re?glementationre?glementation re?gissantre?gissant les recherches impliquant la personne humaine, au sens de l'Article L.1121-1-1 et l'Article R, pp.1121-1124

, Nous attirons neánmoins votre attention sur le fait que, dans ce contexte, du fait de l'enregistrement des diffe?rentesdiffe?rentes donneés et informations, il vous appartient de vous renseigner sur les obligations lieés aux de?clarationsde?clarations aupre? s de la CNIL Veuillez agréer, Monsieur, l'expression de nos salutations distinguées

, If not previously started, an antimicrobial therapy must be started intra-operatively but there is not consensus about the ideal empirical treatment. The aim of this study was to analyze and report the bacterial epidemiology and prognosis of AGI in the intensive care unit (ICU) in order to reassess this empirical therapy, Le Responsable du Comite?dComite?d'éthique pour la recherche en Anesthe?sieAnesthe?sie-Reánimation Pr. JE. BAZIN SFAR - 74 rue Raynouard 75016 Paris www.sfar.org contact : cerar@sfar.org ABSTRACT Background, 2008.

, Echinocandin was added if aorto-enteric fistula (AEF) was suspected. Primary outcome was the appropriateness of antibiotherapy. Thirty-day and in-hospital mortality were defined as secondary outcome. Results: During the study period

, Using a combination of carbapenem with anti MRSA as initial empirical treatment, we would achieve 99% coverage with the first line treatment. Thirty-day mortality rate was 24% and in hospital mortality rate was 37%. Conclusion: Aortic graft infection carries high morbidity and mortality rates. We recommend the use of carbapenem with anti-MRSA as first line antibiotherapy in AGI, Gram positive cocci (GPC) were the most commonly implicated (n=104), with streptococci (n=39)